IP Library › Patent Application 10984393
Patent Application
App. No. 10/984,393

Crystalline pharmaceutical

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/984,393
Abstract

New crystalline forms of lopinavir are disclosed.

Claims (23)

1 . A crystalline hydrated form of lopinavir.

2 . The crystalline form of lopinavir of claim 1 with a peak in the solid state infrared spectrum at a position within the range 1652-1666 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1606-1615 cm −1 .

3 . A substantially pure crystalline hydrated form of lopinavir.

4 . The crystalline form of lopinavir of claim 3 with a peak in the solid state infrared spectrum at a position within the range 1652-1666 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1606-1615 cm −1 .

5 . A solvated crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1661-1673 cm −1 , a peak in the solid state infrared spectrum at a position within the range 1645-1653 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1619-1629 cm −1 .

6 . A substantially pure solvated crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1645-1673 cm −1 , a peak in the solid infrared spectrum at a position within the range 1645-1653 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1619-1629 cm −1 .

7 . A crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 .

8 . A crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1636-1647 cm −1 .

9 . A substantially pure crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 .

10 . A substantially pure crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1636-1647 cm −1 .

11 . A solvated crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 .

12 . A solvated crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1636-1647 cm −1 .

13 . A substantially pure solvated crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 .

14 . A substantially pure solvated crystalline form of lopinavir with a peak in the solid state infrared spectrum at a position within the range 1655-1662 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1636-1647 cm −1 .

15 . A non-solvated crystalline form of lopinavir.

16 . The crystalline form of lopinavir of claim 15 with a peak in the solid state infrared spectrum at a position within the range 1680-1685 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1625-1630 cm −1 .

17 . The crystalline form of lopinavir of claim 15 with characteristic peaks in the ponder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1° and 18.53°±0.1°.

18 . The crystalline form of lopinavir of claim 15 with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 10.80°±0.1°, 12.04°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1°, 18.26°±0.1°, 18.53°±0.1°, 20.47°±0.1° and 25.35°±0.1°.

19 . A substantially pure non-solvated crystalline form of lopinavir.

20 . The crystalline form of lopinavir of claim 19 with a peak in the solid state infrared spectrum at a position within the range 1680-1685 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1625-1630 cm −1 .

21 . The crystalline form of lopinavir of claim 19 with a peak in the solid state infrared spectrum at a position within the range 1680-1685 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1668-1674 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1656-1662 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1642-1648 cm −1 and a peak in the solid state infrared spectrum at a position within the range 1625-1630 cm −1 .

22 . The crystalline form of lopinavir of claim 19 with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1° and 18.53°±0.1°.

23 . The crystalline form of lopinavir of claim 19 with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of 6.85°±0.1°, 9.14°±0.1°, 10.80°±0.1°, 12.04°±0.1°, 12.88°±0.1°, 15.09°±0.1°, 17.74°±0.1°, 18.01°±0.1°, 18.26°±0.1°, 18.53°±0.1°, 20.47°±0.1° and 25.35°±0.1°.